CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00398-07v1
15/3/425    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Perry, S.
Right arrow Articles by Parsonnet, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perry, S.
Right arrow Articles by Parsonnet, J.
Clinical and Vaccine Immunology, March 2008, p. 425-432, Vol. 15, No. 3
1071-412X/08/$08.00+0     doi:10.1128/CVI.00398-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Reproducibility of QuantiFERON-TB Gold In-Tube Assay{triangledown}

Sharon Perry,1* Luz Sanchez,1 Shufang Yang,1 Zubin Agarwal,1 Philip Hurst,2 and Julie Parsonnet1

Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California,1 Santa Clara Valley Health and Hospitals System, San Jose, California2

Received 3 September 2007/ Returned for modification 7 November 2007/ Accepted 6 January 2008

Studies are needed to characterize the reproducibility of QuantiFERON-TB Gold (QFT-G) for targeted U.S. screening populations. Members of northern California households were tested with the QFT-G in-tube assay (QFT-G-IT) at two home visits 3 months apart. Reproducibility and agreement with the tuberculin skin test (TST) were assessed. Monte Carlo simulation was used to evaluate the role of test-related error. Of 63 individuals (49 adults and 14 children) completing QFT-G-IT at both time points, 79% were foreign-born (98% from Latin America) and 68% reported Mycobacterium bovis BCG vaccination. At the baseline visit, 23 (37%) were TST positive and 15 (24%) were QFT-G-IT positive ({kappa} = 0.48 [± 0.11]). At 3 months, 3/48 (6.3%; 95% confidence interval [95CI], 2 to 17) of those initially QFT-G-IT negative converted, and 5/15 (33%; 95CI, 15 to 58) of those initially QFT-G-IT positive reverted. Among the 8 individuals with inconsistent QFT-G-IT results, the maximum gamma interferon response at either visit was 0.68 IU/ml versus means of 4.99 (± 3.74) and 6.95 (± 5.6) for 10 persistent positives at the first and second visits, respectively. Expected false-reversion and -conversion rates were 32% (90CI, 25 to 39%) and 6.95% (90CI, 4.6 to 9.8%) when the sensitivity and specificity were assumed to average 70% and 98%, respectively. Transient responses to QFT-G-IT are common, and low positive results need to be interpreted with caution. Further studies are needed to characterize the predictive value of the test for U.S. foreign-born and other targeted screening populations.


* Corresponding author. Mailing address: Stanford University, 300 Pasteur Drive, S131 Grant Bldg., Stanford, CA 94305-5407. Phone: (415) 505-3048. Fax: (650) 725-3584. E-mail: shnperry{at}stanford.edu

{triangledown} Published ahead of print on 16 January 2008.


Clinical and Vaccine Immunology, March 2008, p. 425-432, Vol. 15, No. 3
1071-412X/08/$08.00+0     doi:10.1128/CVI.00398-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.